Clinical Trials Using Bendamustine Hydrochloride

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Bendamustine Hydrochloride. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-18 of 18
  • A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

    This open-label, multicenter, global study is designed to determine the recommended phase 2 dose, safety, efficacy, and pharmacokinetics / pharmacodynamics of durvalumab in subjects with certain lymphoma subtypes or CLL. Globally, 265 subjects may be enrolled into 4 treatment arms, including durvalumab monotherapy; durvalumab in combination with lenalidomide± rituximab; ibrutinib; or rituximab ± bendamustine. The study will have 3 parts: dose finding, dose confirmation, and dose expansion. Subjects receiving monotherapy may receive combination therapy or involved-field radiation to a single nodal site at time of progressive disease.
    Location: 8 locations

  • Bendamustine Hydrochloride, Rituximab, Ibrutinib, and Venetoclax in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma

    This phase I trial studies the side effects and best dose of venetoclax when giving together with bendamustine hydrochloride, rituximab, and ibrutinib in treating patients with mantle cell lymphoma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as bendamustine hydrochloride and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bendamustine hydrochloride, rituximab, ibrutinib, and venetoclax may work better in treating patients with mantle cell lymphoma.
    Location: 6 locations

  • A Study of TAK-659 in Combination With Bendamustine (+ / -Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

    The purpose of this study is to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of TAK-659 when administered in combination with bendamustine, bendamustine + rituximab, gemcitabine, lenalidomide, or ibrutinib.
    Location: 4 locations

  • Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and / or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R / R DLBCL)

    Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in combination with various agents for the treatment of Relapsed / Refractory (R / R) Diffuse Large B-Cell Lymphoma (DLBCL).
    Location: 3 locations

  • Ublituximab in Combination With TGR-1202 + / - Ibrutinib or Bendamustine in Patients With B-cell Malignancies

    The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with TGR-1202, with or without ibrutinib or bendamustine, in patients with advanced hematologic malignancies
    Location: 3 locations

  • A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)

    This is an open-label, multicenter, phase 2 clinical trial designed to evaluate the efficacy and safety of brentuximab vedotin as a single-agent (Part A) and in combination with dacarbazine (Part B), bendamustine (Part C), or nivolumab (Part D) in front-line therapy of HL in adults age 60 and above.
    Location: 2 locations

  • Everolimus and Bendamustine Hydrochloride in Treating Patients with Relapsed or Refractory Hematologic Cancer

    This phase I trial studies the side effects and the best dose of everolimus when given together with bendamustine hydrochloride in treating patients with cancer of the blood (hematologic cancer) that has returned after a period of improvement (relapsed) or did not get better with a particular treatment (refractory). Everolimus may prevent cancer cells from growing by blocking a protein that is needed for cell growth. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving everolimus together with bendamustine hydrochloride may be a better treatment for hematologic cancer.
    Location: University of California Davis Comprehensive Cancer Center, Sacramento, California

  • Carfilzomib, Bendamustine Hydrochloride, and Rituximab in Treating Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    This phase Ib trial studies the side effects and best dose of carfilzomib when given together with bendamustine hydrochloride and rituximab in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous treatment. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving carfilzomib together with bendamustine hydrochloride and rituximab may be a better treatment for B-cell non-Hodgkin lymphoma.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • CPI-613 and Bendamustine Hydrochloride in Treating Patients with Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

    This phase I trial studies the side effects and best dose of CPI-613 when given together with bendamustine hydrochloride in treating patients with T-cell non-Hodgkin lymphoma or Hodgkin lymphoma that has returned or does not respond to treatment. CPI-613 may kill cancer cells by turning off their mitochondria, which are used by cancer cells to produce energy and are the building blocks needed to make more cancer cells. By shutting off mitochondria, CPI-613 may deprive the cancer cells of energy and other supplies needed to survive and grow. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving CPI-613 with bendamustine hydrochloride may kill more cancer cells.
    Location: Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina

  • Donor Natural Killer Cell Infusion after Autologous CD133+ Selected Stem Cell Transplant in Treating Younger Patients with High Risk Solid Tumors or Lymphomas

    This pilot clinical trial studies whether a donor natural killer cell infusion can be safely used after autologous cluster of differentiation (CD)133+ selected stem cell transplant in treating younger patients with solid tumors or lymphomas that are likely to come back or spread. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. An autologous transplant means that stem cells are collected from the patient's blood and stored. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Stem cell selection is used to separate stem cells from other cells collected, which may include tumor cells. A natural killer cell is a type of white blood cell that has small particles with enzymes that can kill tumor cells. Adding a haploidentical donor (partially matched family member donor) natural killer cell infusion after an autologous stem cell transplant may help treat younger patients with high risk solid tumors or lymphomas.
    Location: St. Jude Children's Research Hospital, Memphis, Tennessee

  • Carfilzomib in Combination with Bendamustine Hydrochloride and Dexamethasone in Treating Patients with Newly Diagnosed Multiple Myeloma

    This phase I / II trial studies the best dose and safety of carfilzomib when given together with bendamustine hydrochloride and dexamethasone in treating patients with newly diagnosed multiple myeloma. Carfilzomib and bendamustine hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carfilzomib together with bendamustine hydrochloride and dexamethasone may be a better treatment for multiple myeloma.
    Location: Columbia University / Herbert Irving Cancer Center, New York, New York

  • Bendamustine Hydrochloride and Rituximab Followed by Rituximab and Lenalidomide in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    This phase II trial studies how well bendamustine hydrochloride and rituximab followed by rituximab and lenalidomide work in treating patients with previously untreated chronic lymphocytic leukemia or small cell lymphocytic lymphoma. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or stopping them from spreading. Monoclonal antibodies, such as rituximab, block cancer growth in different ways by targeting certain cells. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving bendamustine hydrochloride and rituximab followed by rituximab and lenalidomide may kill more cancer cells.
    Location: University of Wisconsin Hospital and Clinics, Madison, Wisconsin

  • Bendamustine Hydrochloride, Pomalidomide, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma

    This phase I / II trial studies the side effects and best dose of bendamustine hydrochloride and pomalidomide when given together with dexamethasone and to see how well they work in treating patients with multiple myeloma that has come back or is not responding to treatment. Drugs used in chemotherapy, such as bendamustine hydrochloride and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Biological therapies, such as pomalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving bendamustine hydrochloride and pomalidomide together with dexamethasone may kill more cancer cells.
    Location: Duke University Medical Center, Durham, North Carolina

  • Inotuzumab Ozogamicin, Fludarabine Phosphate, Bendamustine Hydrochloride, and Rituximab before Donor Stem Cell Transplant in Treating Patients with Lymphoid Malignancies

    This phase I / II trial studies the side effects and the best dose of inotuzumab ozogamicin when given together with fludarabine phosphate, bendamustine hydrochloride, and rituximab before donor stem cell transplant in treating patients with lymphoid malignancies. Giving chemotherapy drugs, such as fludarabine phosphate and bendamustine hydrochloride, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells or abnormal cell and helps stop the patient's immune system from rejecting the donor's stem cells. Monoclonal antibodies, such as inotuzumab ozogamicin and rituximab, interfere with the ability of cancer cells to grow and spread. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cell from a donor can make an immune system response against the body's normal cells. Giving fludarabine phosphate and bendamustine hydrochloride before the transplant together with anti-thymocyte globulin and tacrolimus may stop this from happening.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Bendamustine Hydrochloride, Ofatumumab, Carboplatin, and Etoposide in Treating Patients with Relapsed or Refractory Aggressive B-cell Lymphoma

    This phase I / II trial studies the side effects and best dose of bendamustine hydrochloride when given together with ofatumumab, carboplatin, and etoposide and to see how well they work in treating patients with aggressive B-cell lymphoma that has returned after a period of improvement or does not respond to treatment. Drugs used in chemotherapy, such as bendamustine hydrochloride, carboplatin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Etoposide may also stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as ofatumumab, may interfere with the ability of cancer cells to grow and spread. Giving bendamustine hydrochloride, ofatumumab, carboplatin, and etoposide together may kill more cancer cells.
    Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

  • Ofatumumab with or without Bendamustine Hydrochloride in Treating Patients with Mantel Cell Lymphoma That Are Ineligible for Stem Cell Transplant

    This phase II trial studies ofatumumab with or without bendamustine hydrochloride in treating patients with mantle cell lymphoma (MCL) that are ineligible for stem cell transplant. Monoclonal antibodies, such as ofatumumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or stopping them from spreading. It is not yet known whether ofatumumab is more effective when given together with or without bendamustine hydrochloride in treating patients with MCL.
    Location: Memorial Sloan-Kettering Cancer Center, New York, New York

  • Rituximab and Pentostatin or Bendamustine Hydrochloride in Treating Patients with Relapsed or Refractory Hairy Cell Leukemia

    This randomized phase II trial studies how well rituximab and pentostatin or bendamustine hydrochloride works in treating patients with hairy cell leukemia that has come back after a period of improvement or does not responded to treatment. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as pentostatin and bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether rituximab is more effective with pentostatin or bendamustine hydrochloride in treating recurrent hairy cell leukemia.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

    Patients with high tumor burden, low grade follicular lymphoma that has never been treated, will receive venetoclax in combination with obinutuzumab and bendamustine. Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with follicular lymphoma. Venetoclax may help to slow down the growth of cancer or may cause cancer cells to die. The purpose of this study is to see whether adding venetoclax to obinutuzumab and bendamustine improves the response (the tumor shrinks or disappears) in patients with follicular lymphoma.
    Location: 3 locations